ALKS

Alkermes plc NMS · ALKS

$51.95 +0.23 (+0.44%)

Neutral · +0.51σ

+ Compare Open in Sniper

Mkt cap $8.7B

P/E 57.7

Day $51.25 – $52.25

52wk $27.00 – $55.67

Avg vol 2.2M

Beta 0.29

Div yld —

Next earnings 2026-07-28

Quick read

Plain English

ALKS last traded at $51.95, up 0.4% on the day; that's in the upper part of its 52-week range ($27.00–$55.67). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-07-28) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, +0.43 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, +0.43 ATR from EMA21 · no notable pattern

· Aligned with breakout up (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 6 · tech 6 / 80 · support 0 / 20

below KC1 upper, +0.43 ATR from EMA21 · no notable pattern

· Counter-trend short in breakout up

How this grade was earned

total 6 pts

Cycle position 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $40.15 (fair range $14–$40); today's price sits 29% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$40.15

Fair-value range

$13.64 – $40.15

Margin of safety

-29%

Verdict

Overvalued

Accounting quality Weak

✓ Current ratio 3.55 (antifragile)
✓ Debt/equity 0.37 (antifragile)
✓ Goodwill 3% of assets (organic growth)
✓ Gross margin 87% (pricing power)

⚠ Debt exceeds cash
⚠ Negative retained earnings
⚠ Inventory growing faster than revenue

Price implies ~29% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

ALKS is a $8.7 billion company, priced at 58× last year's earnings, and it moves more calmly than the market (beta 0.3); the stock is trading near the top of its 52-week range.

Mkt cap $8.7B

P/E ttm 57.7

Fwd P/E 31.7

Beta 0.29

Day range $51.25 – $52.25

52w range $27.00 – $55.67

Avg vol 2.2M

RSI(2) 45.8

ROE 9.4%

Net mgn 9.8%

FCF mgn 9.0%

Debt/Eq 0.90

Div yld —

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Next earn 2026-07-28

52-week range · today's price

$27.00$55.67

More on ALKS

Options idea

See more →

CALL $55 2026-08-21

$2.45

PUT $50 2026-08-21

$2.40

Earnings

See more →

Last reported: 2026-05-05
EPS (act / est): 0.38 / -0.04
Surprise: +1053.0%
Next report: 2026-07-28

About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophren…